Campylobacter jejuni is responsible for 90% of food-borne acute gastroenteritis. In most cases, the condition is self-limited; however, patients with a Campylobacter infection typically experience diarrhoea that is either bloody or mucoid. Additionally, complications such as bacteraemia, meningitis, and reactive arthritis can arise, particularly in immunocompromised individuals who may require antimicrobial treatment and hospitalisation [3, 4]. Commonly used antimicrobial drugs for treating Campylobacter infections include macrolides, such as erythromycin and azithromycin. Other treatment options include aminoglycosides, tetracyclines, and fluoroquinolones, such as ciprofloxacin, and antimicrobial resistance is a global issue. Aim of Study: To determine the antimicrobial resistance rates and the presence of virulence genes in Campylobacter jejuni isolates. Materials and Methods: 62 Campylobacter isolates were obtained. Antimicrobial susceptibility was done and interpreted. Genomic DNA was extracted, and detection of virulence genes was done by monoplex and multiplex PCR. Results: The study found that C. jejuni isolates showed resistance to erythromycin, tetracycline, and ciprofloxacin, with flaB, pldA, cdtA, and cdtC virulence genes present. H. pylori was prevalent in erythromycin resistance, tetracycline resistance, and ciprofloxacin resistance, with a significant correlation between erythromycin and tetracycline resistance and refractory H. pylori. Conclusion: Resistance of Campylobacter jejuni to antimicrobials was high, especially to ciprofloxacin, and resistant H. pylori infection should be excluded.